ClinicalTrials.gg
RecruitingNCT06456489Updated Jun 13, 2024

Pulse Steroid Injection in Refractory Rheumatoid Arthritis

A Phase 3 interventional study of Solumedrol in Active Rheumatoid Arthritis, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-06-13.

Sponsored by Sohag University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
268
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Arthritis, Rheumatoid by Sohag University — 10 open to participants now, 11 under way, 1 of them phase 3. Arthritis, Rheumatoid · Sohag University.

Started
2024
with 2 others
Phase 3
Only one
of the 20
Primary completion
2024-09
later than 0 of 10 live
Registered
9th of 20
by date

Among the 20 studies in Arthritis, Rheumatoid by Sohag University, this one is one of 3 that started in 2024, is the only one in phase 3, reaches primary completion later than 0 of the 10 other live ones, and was the 9th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

10 of the 20 studies in Arthritis, Rheumatoid by Sohag University are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Arthritis, Rheumatoid by Sohag University, or all of them as a file.
02

Study summary

Remission or low disease activity in active rheumatoid arthritis

Read the detailed description

Assessment of rheumatoid arthritis activity by Disease activity score DAS28, DAS28 Erythrocyte sedimentation rate (ESR), American college of rheumatology (ACR) 20, ACR 50, ACR 70 will be done at baseline and every month for 3 consecutive months for both groups.

03

Conditions studied

  • Active Rheumatoid Arthritis
04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • rheumatoid arthritis patients

Exclusion criteria

Exclusion Criteria:

  • Other connective tissue diseases
  • Endocrine diseases such as DM and thyroid disorders
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
268 participants (estimated)

Study arms

  • Experimental
    pulse steroid solumedrol

    125 mg of methylprednisolone IV pulse will be administered for two consecutive days followed by oral steroid for 2 weeks with gradual withdrawal.

    Drug: Solumedrol

  • Placebo comparator
    without pulse

    patients will not receive any additional treatment

    Drug: Solumedrol

Interventions

06

What researchers measure

Primary outcomes

  1. remission or low disease activity

    Outcome measurements for both groups will be done at baseline and every month for 3 months. DAS28, DAS28 ESR ACR20 ACR50 ACR70

    Time frame: 4 months

07

Study locations

1 of 1 sites recruiting
  • Al-Azhar Univrsity
    Cairo, Egypt
    Recruiting
    • Al-Azhar Universiy · Contactinfo@azharegypt.net · 01026912179
    • Al-Azhar Universiy · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Sep 2024, 4 months after the start.

Of 148 phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 40. This study's planned 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2024
First posted
Jun 13, 2024
StartActual
May 1, 2024
Primary completionEst.
Sep 30, 2024
CompletionEst.
Dec 31, 2024
Last update
Jun 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06456489
Lead sponsor
Sohag University
Responsible party
Ahmed Mahrous (Prof., Sohag University) — Principal investigator
First posted
Jun 13, 2024
Start date
May 1, 2024
Primary completion
Sep 30, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Jun 13, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methylprednisolone Hemisuccinate

Start the discussion